



Application No. 08/949,904
Docket No. 31896-52000 (GI5288B)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)
Serial No. 08/949,904) Examiner: Ungar
Filed: 15-October-97) Group Art Unit: 1642
For: Human SDF-5 Protein and Compositions)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. § 1.97 and § 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The fee in the amount of \$180 is being submitted to comply with the provisions of 37 C.F.R. § 1.97(c). Please charge such fee to Deposit Account No. 19-2380.

It is requested that the accompanying PTO-1449 be considered and made of record in the above-identified application. To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initial a copy of this form be returned to the undersigned.


The Commissioner is hereby authorized to charge any fees connected with this filing which may be required now, or credit any overpayment to Deposit Account No. 19-2380.

Respectfully submitted,


Raymond Van Dyke
Reg. No. 34,746

Date: April 14, 2004

NIXON PEABODY LLP
Suite 900
401 9th Street, N.W.
Washington, DC 20004-2128
Telephone: (202) 585-8000



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	08/949,904
				Filing Date	15-October-97
				First Named Inventor	LaVallie
				Art Unit	1642
				Examiner Name	Ungar
Sheet	1	of	1	Attorney Docket Number	31896-52000 (GI5288B)

U.S. PATENT DOCUMENTS					
Examiner Initials [*]	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	1	PCT WO 01/19855 A2	03/22/2001	Bodine, P.V.N.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	2	BANERJEE, C. et al., Differential Regulation of the Two Principal Runx2/Cfa1 N-Terminal Isoforms in Response to Bone Morphogenetic Protein-2 during Development of the Osteoblast Phenotype, Endocrinology, September 2001, 4026-4039, 142(9), Endocrine Society, U.S.	
	3	GILBERT, J., Current Treatment Options for Restoration of Articular Cartilage, American Journal of Knee Surgery, Winter 1998, 11(1), 43-46	
	4	KRONENBERG, H., Development Regulation of the Growth Plate, Nature, 15 May 2003, 423, 332-336, Nature Publishing Group	
	5	PEARSON, D. AND SASSE, J., Differential Regulation of Biglycan and Decorin by Retinoic Acid in Bovine Chondrocytes, JBC, 15 December 1992, 267(35), 25364-25370, American Society for Biochemistry and Molecular Biology, U.S.	
	6	LEIMEISTER, C., et al., Developmental Expression Patterns of Mouse sFRP Genes Encoding Members of the Secreted Frizzled Related Protein Family, 28 April 1998, Mechanisms of Development 75 (1998) 29-42	
	7	BODINE, P.V.N., et al., Functional Properties of a Conditionally Phenotypic, Estrogen-Responsive, Human Osteoblast Cell Line, (1997), Journal of Cellular Biochemistry 65:368-387, Wiley-Liss, Inc.	
	8	COGHLAN, M.P., et al., Selective Small Molecule Inhibitors of Glycogen Synthase Kinase-3 Modulate Glycogen Metabolism and Gene Transcription, 7 September 2000, Chemistry & Biology 2000, 7:793-803, Elsevier Science Ltd.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.